



Vaccine Efficacy and Safety in People with Kidney Diseases/Kidney Transplant Recipients

Guest Editor:

Dr. Claudius Speer

Department of Nephrology,
Heidelberg University Hospital,
69120 Heidelberg, Germany

Deadline for manuscript
submissions:

31 January 2025

Message from the Guest Editor

The COVID-19 pandemic unmasked the impact of extrinsic immunosuppression, as in kidney transplant recipients, or intrinsic immunosuppression, as in ESRD patients with chronic inflammation and immune senescence with exceptionally high lethality. Immunocompromised cohorts with kidney diseases have a significantly impaired SARS-CoV-2 vaccine response compared with healthy subjects, even to new mRNA vaccines.

With the upcoming different Omicron variants characterized by immune escape, novel vaccination strategies, including adapted mRNA vaccines against epitopes of emerging variants, are needed to protect high-risk individuals. However, further research is needed to fully understand the efficacy and safety of these bivalent vaccines against emerging variants. This Special Issue specifically welcomes (1) the submission of manuscripts that address efficacy, immunogenicity, and long-term immune response after bivalent COVID-19 vaccination, and (2) studies of non-COVID-19 vaccines that examine humoral and cellular immunity to various vaccines in immunocompromised individuals with kidney disease.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com